Blue Jet Healthcare profit drops 19% as it eyes ₹1,000 cr fundraise
Annual profit fell to ₹248 crore on an 8% revenue decline, while the board approved a ₹1,000 crore capital raise for expansion.
— 1 earlier story on Blue Jet Healthcare Ltd. →What's new
- FY26 net profit fell 19% to ₹248 crore.
- Revenue slipped 8% to ₹947 crore due to pharma intermediate inventory headwinds.
- Board approved a ₹1,000 crore fundraise to back new greenfield and R&D projects.
Why this matters
The company is betting heavily on future capacity despite a difficult year. A ₹1,000 crore raise is significant, representing roughly 13% of its current market capitalization.
What we're watching
- The timeline for the QIP and its impact on shareholder dilution.
- Progress on the Vizag greenfield project and Hyderabad R&D expansion.
- Signs of recovery in the pharma intermediates business segment.
The full read
Blue Jet Healthcare struggled through FY26, as net profit slid 19% to ₹248 crore and revenue dropped 8% to ₹947 crore. The company blamed persistent inventory headwinds in its pharma intermediates business for the performance. Despite the weak results, the board is looking ahead, approving a plan to raise up to ₹1,000 crore through a qualified institutional placement or similar equity-linked instruments. This capital is earmarked for a ₹1,000 crore greenfield project in Vizag and R&D expansion in Hyderabad. The raise is material, amounting to approximately 13% of the company's market capitalization. While the results were soft, the statutory auditors provided an unmodified opinion. The company also declared a final dividend of ₹1.2 per share. The next test is how quickly the company can deploy this new capital to reverse the current downward trend in its core business.
Questions answered
- How did Blue Jet perform in FY26?
- The company reported a 19% decline in net profit to ₹248 crore, with revenue falling 8% to ₹947 crore.
- What is the primary reason for the revenue decline?
- Management cited persistent inventory headwinds within its pharma intermediates business as the cause for the revenue drop.
- What is the purpose of the proposed ₹1,000 crore fundraise?
- The company plans to use the capital to support a new greenfield project in Vizag and expand its R&D operations in Hyderabad.
- What dividend did the board recommend?
- The board recommended a final dividend of ₹1.2 per share.
Story so far
All notes on BLUEJET →- Today · 12:43 PM IST Blue Jet Healthcare profit drops 19% as it eyes ₹1,000 cr fundraise
- today Blue Jet Healthcare confirms FY26 results and ₹1,000 crore fundraise